YOLFTbeta
REGENT PACIFIC GRP

REGENT PACIFIC GRP

RPG · F · Healthcare / Drug Manufacturers - Specialty & Generic

0.093EUR+0.00 (+1.09%)

Price History

Full chart

Market Stats

Previous Close0.092
Open0.092
Day Range0.092 – 0.093
52-Week Range0.059 – 0.121
Volume0
Market Cap25.68M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.01
Dividend Yield0.00%
Beta1.08
50-Day Avg0.0916
200-Day Avg0.0889

About

Regent Pacific Group Limited, an investment holding company, focuses on healthcare and life sciences sectors in the United States, Europe, and Asia Pacific. The company operates through two segments, Biopharma and Corporate Investment. It is involved in the research, development, manufacturing, marketing, and sale of pharmaceutical products for the treatment and management of urological disorders; and development of AI system for the field of biological aging clocks, at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. The company also invests in listed and unlisted corporate entities. In addition, it provides management services. The company was formerly known as Endurance RP Limited and changed its name to Regent Pacific Group Limited in July 2023. Regent Pacific Group Limited was founded in 1991 and is headquartered in Central, Hong Kong.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Jamie Alexander Gibson
  • Employees15
  • HeadquartersHenley Building, Central, Hong Kong, Germany
  • Websitehttps://www.regentpac.com

Leadership

  • Mr. Jamie Alexander GibsonCEO & Executive Director · b. 1966
  • Dr. Michael Grant Wyllie BScCo-Founder & Chief Scientific Officer · b. 1951
  • Mr. Yui Fui WongChief Financial Officer · b. 1975
  • Mr. Paul Eric Jones BA, MBAInvestment Director · b. 1965
  • Ms. Mei Yan LuiCompany Secretary · b. 1975
  • Prof. John Michael Fitzpatrick FC Urol (SA), FRCS, FRCSGlas, FRCSI, MChChairman of Clinical Scientific Advisory Board

Financials

Income Statement

Currency: USD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue3.25M114.00K291.00K719.00K363.00K
Growth (%)--96.50%+155.26%+147.08%-49.51%
Cost of Revenue3.61M2.96M2.72M2.84M-
Gross Profit-355.00K-2.85M-2.43M-2.12M-
Gross Margin-10.91%-2500.00%-836.08%-294.99%-
Operating Expense28.03M27.90M25.53M2.07M-
Operating Income-28.39M-30.75M-27.96M-4.19M-4.30M
Operating Margin-872.37%-26977.19%-9608.59%-582.61%-1183.75%
EBITDA--9.56M-7.72M-4.33M-4.33M
EBITDA Margin--8385.09%-2653.95%-602.09%-1193.94%
Net Income-12.60M-36.43M-25.05M-4.48M-4.71M
Net Income Margin-387.15%-31953.51%-8607.90%-623.37%-1297.52%
R&D2.40M1.22M1.38M938.00K783.00K
R&D as % of Total Revenue73.88%1071.05%473.88%130.46%215.70%
Interest Expense1.22M1.01M80.00K171.00K368.00K
Interest Expense % of Total Revenue37.43%888.60%27.49%23.78%101.38%

Balance Sheet

Currency: USD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets62.23M26.32M2.79M610.00K571.00K
Total Liabilities23.46M23.72M4.35M6.51M7.21M
Total Equity38.77M2.60M-1.55M-5.90M-6.64M
Cash613.00K309.00K2.10M100.00K135.00K
Net Debt12.61M13.12M-2.48M3.49M

Cash Flow

Currency: USD2012-12-312013-12-312014-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow----1.70M506.00K-3.81M-4.13M-4.30M
Capital Expenditure00043.00K12.00K2.00K6.00K15.00K
Free Cash Flow----1.75M494.00K-3.81M-4.13M-4.31M
FCF to OCF---102.52%97.63%100.05%100.15%100.35%

Key Statistics & Ratios

Market Cap25.68M
Enterprise Value32.72M
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales4.75
Price / Book2.06
EPS-0.01
Book Value-0.0185
Revenue (TTM)5.40M
Gross Profit (TTM)4.52M
EBITDA138.00K
Profit Margin-36.12%
Operating Margin45.78%
Return on Equity-186.32%
Return on Assets2.51%
Shares Outstanding291.82M
Shares Float92.02M
Beta1.08
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20132×
2.90Feb 18, 20132.90Feb 8, 2013
20121×
0.67Jan 16, 2012
20111×
0.45Jan 4, 2011
20101×
0.22Jun 3, 2010
20091×
0.11Sep 24, 2009
20041×
4.76Jul 30, 2004

Stock Splits

  • Jun 5, 20231:20
  • Jun 10, 20161:10